Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million

On March 19, 2026 Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, reported that it has entered into a securities purchase agreement (the "SPA") with new and existing healthcare focused institutional investors. The financing is for gross proceeds of up to approximately $31.4 million to the Company, including initial gross proceeds of approximately $10.5 million and up to an additional $20.9 million in gross proceeds upon the potential cash exercise of accompanying warrants at the election of the investors. The transaction is expected to close on or about March 20, 2026, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participating investors include institutional healthcare focused funds, Stonepine Capital and Nantahala Capital as well as other institutional funds and individual healthcare professionals, along with certain Company insiders, including the Company’s Chief Executive Officer.

The financing enables Azitra to utilize its expertise in skin science and leverage its microbial genetic engineering platform to produce high value proteins and peptides for the cosmetic market. The market for biotech oriented cosmetic ingredients reached $2.3 billion in 2024 and is projected to grow to $3.7 billion by 20301. The new initiatives drive near term value creation opportunities by streamlining the time to commercialization and opening up a new universe of new potential strategic partners.

"Azitra is thrilled to be accelerating its new program focused on developing its proprietary filaggrin protein and peptide technologies for the consumer, cosmeceutical market," said Chief Executive Officer, Francisco Salva. "We are confident these technologies offer an exciting new way to address the appearance of fine lines and wrinkles as well as dry sensitive skin and eczema-like rashes. Over the last two decades, research has evolved to understand that such issues are not just the result of immune system overdrive but are commonly driven by a physical barrier deficiency caused by a lack of sufficient filaggrin protein and subsequent breakdown into peptides and natural moisturizing factors."

Pursuant to the terms of the SPA, the Company is selling to investors in the financing an aggregate of (i) 10,470 shares of Series A convertible non-redeemable preferred stock (the "Series A Preferred Stock"), (ii) Series B warrants (the "Series B Warrants") to purchase up to 85,101,201 shares of the Company’s common stock, par value $0.0001 ("Common Stock") and (iii) Series C warrants (the "Series C Warrants") to purchase up to 85,101,201 shares of Common Stock, (the Series B Warrants together with the Series C Warrants, the "Warrants"). Each share of Series A Preferred Stock is being sold together with a Series B Warrant to purchase 8,129 shares of Common Stock and a Series C Warrant to purchase 8,129 shares of Common Stock. The Series A Preferred Stock was sold at a purchase price of $1,000 per share to the investors. The Warrants will each have an exercise price of $0.123 per share, subject to adjustment in certain circumstances. In accordance with the terms of the Warrants, in certain circumstances, pre-funded warrants to purchase shares of Common Stock may be issued upon exercise of the Warrants (the "Pre-Funded Warrants").

Each share of Series A Preferred Stock will automatically convert into approximately 8,129 shares of Common Stock upon the approval of the Company’s stockholders and subject to certain beneficial ownership limitations set by each holder. Holders will receive Pre-Funded Warrants in lieu of shares of Common Stock upon conversion of the Series A Preferred Stock to avoid going above the beneficial ownership limitation. The Warrants will be exercisable following the receipt of approval by the Company’s stockholders. The Series B Warrants will terminate 18 months following the date of stockholder approval. The Series C Warrants will terminate, subject to certain exceptions, upon the 30th calendar day following the date on which the Company publicly announces data from its planned human cosmetic study testing the effect of the filaggrin technology.

The issuance of the securities is being made pursuant to exemptions from the registration requirements of the federal and state securities laws. Pursuant to the transaction documents, the Company must register the resale of the shares of common stock issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants.

The Company intends to use the initial net proceeds from the financing, together with the Company’s existing cash and cash equivalents to provide financing for research and development, general corporate expenses, and working capital needs.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

(Press release, Azitra, MAR 19, 2026, View Source [SID1234663745])

Oncoinvent secures new patent expanding protection for Radspherin

On March 19, 2026 Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, reported that the China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin, the Company’s lead product candidate, marking the first approval worldwide within this patent family.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The newly granted patent covers a key technical development to optimize Radspherin’s performance, specifically the size-controlled calcium carbonate microparticle technology. With this grant, patent protection for Radspherin in China is expanded in scope and duration, with a term extending to 2041. This complements the existing composition‑of‑matter patent, which is valid until 2035 (2036 in some jurisdictions). Corresponding patent applications from the same patent family remain under review in several major jurisdictions worldwide.

"We are very pleased to obtain this additional patent in China for Radspherin," said Oystein Soug, Chief Executive Officer at Oncoinvent. "As we continue to advance clinical development, it is essential that our innovation is backed by a strong and durable global intellectual property position."

(Press release, Oncoinvent, MAR 19, 2026, https://www.oncoinvent.com/press-release/oncoinvent-secures-new-patent-expanding-protection-for-radspherin/ [SID1234663708])

Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes

On March 19, 2026 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), reported it will hold an oral presentation outlining new preclinical data on Radio-DARPins at the 3rd Global Radiopharmaceuticals Development Summit, taking place in Shanghai, China on March 19–20, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will outline the Radio-DARPins’ suitability to different isotopes with data on two Radio-DARPin candidates, each specific for a different tumor target. The results of studies in tumor-bearing mice show highly comparable biodistribution profiles for both Radio-DARPin candidates labeled with Lutetium-177 (177Lu) or with Lead-203 (203Pb), with similar uptake and washout rates. Imaging with 177Lu can be indicative of behavior with the therapeutic isotope Actinium-225 (225Ac), and similarly with 203Pb for 212Pb.

"Our recent data confirms that our Radio-DARPin-vector design allows interchangeability of alpha-isotopes, including 212Pb and 225Ac," said Patrick Amstutz, Ph.D., CEO of Molecular Partners. "This feature offers us the opportunity and flexibility to evaluate Radio-DARPin candidates in an isotope-agnostic manner and to choose the most suitable therapeutic isotope, as late as with initial clinical data, without having to restart the entire drug discovery and development process – a significant advantage to tailor our candidates to patient needs."

Details of the presentation

DARPins for targeted alpha therapy: from promising MP0712 first in-human data to opportunities for next Radio-DARPin candidates
Presenter: Daniel Steiner, Ph.D., SVP of Technology and Research
Time: 9:25 am CST, Friday, March 20
Location: Meeting Room B – IND Filing and Clinical Development Progress

The full presentation can be found here.

MP0712, Molecular Partners’ DLL3-targeted 212Pb-based Radio-DARPin candidate co-developed with strategic partner Orano Med, is in an ongoing Phase 1/2a trial in the US (NCT07278479). Imaging data of MP0712 carrying the diagnostic isotope 203Pb under compassionate care are supportive of clinical development plans of MP0712 carrying the therapeutic isotope 212Pb for patients with small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine cancers.

In February 2026, Molecular Partners entered into an agreement with Eckert & Ziegler, leading specialist in isotope-related components for nuclear medicine and radiation therapy, to enable the development and manufacturing of Radio-DARPin therapeutics. Eckert & Ziegler will support Molecular Partners with a comprehensive range of services covering development activities for Radio-DARPins with 225Ac as therapeutic payload and 177Lu as imaging payload.

About Radio-DARPins
Molecular Partners’ Radio-DARPins are designed as ideal vectors for precise delivery of potent alpha-emitting isotopes to tumor lesions and have the potential to unlock a broad range of tumor targets for targeted radiopharmaceuticals. Building on the DARPins’ unique properties, Molecular Partners has developed a proprietary Radio-DARPin platform to address historic limitations of radioligand therapy, such as kidney accumulation and toxicity, and suboptimal tumor uptake. Molecular Partners’ Radio-DARPins addresses these limitations through half-life extension technologies and surface engineering approaches, while preserving the advantages of the small protein format.

(Press release, Molecular Partners, MAR 19, 2026, View Source [SID1234663707])

XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements

On March 28, 2026 XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its 2025 fourth quarter and full year financial results and highlighted recent actions that have the potential to deliver additional shareholder value.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to search for innovative ways to drive enhanced optionality in the XOMA portfolio, with the addition of 22 assets and two platform technologies over the past year," stated Owen Hughes, Chief Executive Officer of XOMA Royalty. "With multiple commercial assets delivering growing royalty receipts, we achieved positive cash flow from operations and were able to return $16 million of capital through a share buyback in 2025. Looking ahead, with 14 programs in registrational studies, we anticipate a number of catalysts over the ensuing years, including several regulatory updates and late-stage clinical readouts in 2026, which, if positive, will further diversify our commercial royalty streams and drive growing free cash flow in 2027 and beyond."

Portfolio Updates

Day One

OJEMDA New Drug Application filing in Japan triggered $2 million milestone in 4Q25

OJEMDA FY 2026 revenue guidance of $225 – $250 million2

In February 2026, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional marketing authorization of OJEMDA3

In March 2026, Day One and Servier announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion4

Zevra Therapeutics

A Marketing Authorization Application for the evaluation of arimoclomol (MIPLYFFA) for the treatment of NPC is under review by the EMA5

Rezolute

In December 2025, Rezolute announced that the Phase 3 clinical study of ersodetug for the treatment of congenital hyperinsulinism ("HI") demonstrated reductions from baseline in hypoglycemia events by self-monitored blood glucose at both ersodetug dose levels, but the reductions were not statistically significant compared to placebo, due to a pronounced study effect6

Rezolute will meet with FDA under its Breakthrough Therapy Designation in the first quarter of 2026 to determine next steps for the program6

Rezolute anticipates topline results of upLIFT, a Phase 3, single-arm, open-label study in participants with tumor HI, in the second half of 20266

Gossamer Bio & Chiesi

In February 2026, Gossamer Bio announced topline results from the Phase 3 PROSERA clinical trial evaluating seralutinib for the treatment of PAH7

Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.0257

Gossamer plans to meet with the U.S. FDA to discuss the path forward7

2
View Source

3
View Source
children-with-relapsed-or-refractory-braf-altered-pediatric-low-grade-glioma-3246394/

4
View Source

5
View Source

6
View Source

7
View Source

Volixibat

Volixibat VISTAS study in primary sclerosing cholangitis (PSC) topline data expected in Q2 20268

Volixibat VANTAGE study in primary biliary cholangitis (PBC) expected to complete enrollment in H2 20268

Business Development Activity

Takeda Strategic Royalty Share Transaction

In December 2025, XOMA amended its collaboration with Takeda

XOMA will receive low to mid-single-digit royalties and up to $852.6 million in potential milestones across nine development-stage assets, including osavampator, which is being evaluated in Phase 3 studies for major depressive disorder; volixibat, which is being evaluated in PSC and PBC; OHB-607, which Oak Hill Bio Ltd and its partner are developing for the prevention of bronchopulmonary dysplasia in extremely premature infants; REC-4881, which is in Phase 2 development for familial adenomatous polyposis; and five early-stage Oak Hill Bio assets

Prior to amending the collaboration, XOMA held a mid-single digit royalty and $16.25 million in potential milestones associated with mezagitamab

Following the transaction, XOMA will retain a low single-digit royalty entitlement on mezagitamab and up to $13.0 million in milestones

Company Acquisitions

Completed or served as the structuring agent in the acquisition of seven companies since the beginning of 2025

Accumulated non-dilutive capital of $11.7 million, net of transaction expenses

Obtained economic interests of approximately 25% in up to $1.1 billion of potential milestone payments and low to mid-single-digit royalties from eight partnered assets

Eligible for 25-70% of proceeds related to any future out license or sale of legacy assets or platform technology from these companies, including the ctLNP delivery platform from Generation Bio

Fourth Quarter and Full-Year 2025 Financial Results

In the fourth quarter of 2025, XOMA Royalty received $3.2 million in cash receipts from royalties and commercial payments and $3.3 million in milestone payments and paid $1.4 million in dividends on the XOMA Royalty Perpetual Preferred stocks. For the full year of 2025, XOMA Royalty received $50.5 million in cash receipts, including $33.6 million in royalties and commercial payments and $16.9 million in milestone payments and fees. During 2025, XOMA Royalty deployed $25.0 million to acquire additional assets for its royalty and milestone portfolio, repurchased 648,048 shares of its common stock for a cost of $16.0 million, and paid $5.5 million in dividends on the XOMA Royalty Perpetual Preferred stocks.

Income and Revenue: Income and revenues for the three months ended December 31, 2025 and 2024, were $13.8 million and $8.7 million, respectively. Income and revenues for the years ended December 31, 2025 and 2024, were $52.1 million and $28.5 million, respectively. The increase in both periods was primarily driven by increased income related to VABYSMO (faricimab-svoa) and OJEMDA (tovorafenib) and milestone payments received from Rezolute and Takeda.

(Press release, Xoma, MAR 18, 2026, View Source [SID1234663757])

Azalea Therapeutics Highlights Nature Publication Demonstrating In Vivo Site-Specific TRAC-CAR T Cell Engineering

On March 18, 2026 Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, reported the publication of foundational research in Nature describing in vivo site-specific genomic integration to reprogram T cells. The research originated as an academic collaboration between the Eyquem laboratory at the University of California, San Francisco and the Doudna laboratory at the University of California, Berkeley. Three of the study’s authors – Justin Eyquem, Ph.D., Jenny Hamilton, Ph.D. and Jennifer Doudna, Ph.D. – subsequently co-founded Azalea Therapeutics to advance precise, programmable in vivo cell engineering toward the development of next-generation in vivo CAR T and other cell-based therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The publication, titled "In vivo site-specific engineering to reprogram T cells," demonstrates that stable and cell-specific transgene expression can be achieved through in vivo integration of large DNA payloads using a two-vector system consisting of enveloped delivery vehicles (EDVs) and adeno-associated viruses (AAVs). In preclinical models, the approach enabled targeted integration of a promoterless chimeric antigen receptor (CAR) transgene at the TRAC locus, resulting in physiologic CAR expression, robust T cell expansion and durable anti-tumor activity.

The research shows that placing CAR expression under control of the endogenous T cell receptor alpha (TRAC) promoter produces regulated CAR expression compared to conventional approaches relying on random integration or constitutive exogenous promoters. In humanized mouse models of B cell aplasia and hematologic malignancies, in vivo-generated TRAC-CAR T cells achieved therapeutic levels of CAR-positive T cells and sustained tumor control.

"This work demonstrates that stable, cell-specific transgene expression can be achieved through in vivo site-specific integration," said Justin Eyquem, Ph.D., co-founder of Azalea Therapeutics and associate professor of medicine at UCSF. "By integrating a promoterless CAR into the TRAC locus, we place expression under control of the endogenous T cell promoter, resulting in physiologic regulation and durable functional activity in preclinical models. These findings establish a foundation for precise in vivo T cell engineering without ex vivo manufacturing."

The research further describes optimization of both delivery components, including evolution of an AAV variant for improved T cell targeting and incorporation of an anti-CD3-targeted EDV to enhance specificity and activation. In humanized mouse models, the optimized system enabled generation of TRAC-CAR T cells representing up to ~20% of splenic T cells following a single administration, accompanied by complete B cell aplasia and tumor clearance.

"The research described in this publication establishes the scientific foundation for precise, programmable CAR insertion directly inside the body," said Jenny Hamilton, Ph.D., co-founder, president and chief executive officer of Azalea Therapeutics. "At Azalea, we are building on these findings with our proprietary EDV-based platform to advance in vivo CAR T programs toward clinical development. Our goal is to generate physiologically regulated, durable CAR T cells in patients through targeted genomic integration, while avoiding the complexity of ex vivo cell manufacturing."

Azalea is advancing TRAC-targeted in vivo CAR T programs toward IND-enabling studies, building on the foundational work described in this publication, which is available online in Nature.

(Press release, Azalea Therapeutics, MAR 18, 2026, View Source [SID1234663733])